posted
MCET is currently a low priced Avian Flu play at the lowest prices in years. Any small news and soar the price of this.
Posts: 137 | Registered: Dec 2004
| IP: Logged |
posted
MultiCell Nominates MCT-465 as Lead Drug Candidate for Evaluation in H5N1 Avian Flu Model WEDNESDAY, NOVEMBER 09, 2005 8:30 AM - BusinessWire
MCET 0.65 -0.04
Enter Symbol:
Enter Keyword:
LINCOLN, R.I., Nov 09, 2005 (BUSINESS WIRE) -- MultiCell Technologies, Inc. (MCET) announced that its subsidiary, MultiCell ImmunoTherapeutics, has elevated MCT-465 to lead drug candidate status and will commence evaluation of MCT-465 in preclinical animal models infected with the H5N1 strain of influenza A virus, known as the "bird flu" or "avian flu" virus. These preclinical studies will seek to build on the success that MCTI's toll receptor molecule and lead drug candidate MCT-465 demonstrated in animal models infected with the H1N1 strain of influenza A virus. In these preclinical studies, originally published in the October 2002 Journal of Clinical Investigation, MCT-465 reduced pulmonary virus titers by 1,000-fold in mouse models, resulting in barely detectable levels of the virus. The results suggest MCT-465 may also be able to reduce influenza A H5N1 viral load. The H5N1 strain of influenza A virus is genetically similar to the H1N1 strain of influenza A virus.
The proposed studies will be designed to determine the effectiveness of MCT-465 to induce immunity in mice infected by the H5N1 influenza A virus. "Based upon our results with influenza A H1N1 virus in mouse models, we believe MCT-465 holds the promise of demonstrating efficacy in H5N1 influenza A animal models," said Dr. Stephen Chang, President of MultiCell. The Company plans additional preclinical studies to further elucidate the underlying immunology, as well as evaluate the manufacturing requirements and toxicology profile of MCT-465 prior to beginning human clinical trials. MultiCell acquired MCT-465 as a result of its acquisition last month of substantially all of the assets of Astral, Inc.
Posts: 2329 | From: MD | Registered: Jul 2005
| IP: Logged |
posted
more like a diabetes play. its been bearish though. been following this one for a long time. i wouldnt get in until .50 range. but thats just me.
Posts: 36 | From: Philadelphia | Registered: Sep 2005
| IP: Logged |
posted
yes but Multicell mostly was interested in diabetic type devices and drugs, and drug delivery right? it was at least 1 year ago when i was more interested in them. its not a 'major' avian flu play. NNVC had a nice fall last week. but i am avioding them for now since it has already done its HUGE runup. NVAX is under heavy accumilation, check out thompsons i-watch for past week, month, i dont think its shorts covering, cause there are no large sell signals. if i were to play a stock, it would be them now at 3$. or HEB if it falls to 2$ range.
Posts: 36 | From: Philadelphia | Registered: Sep 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
this could be niceeee......
